Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.

Abstract

Indacaterol is a novel once-daily long-acting β2-agonist (LABA) for the treatment of chronic obstructive pulmonary disease (COPD) that is currently completing Phase II and Phase III trials. It represents the first of a group of drugs now referred to as the 'ultra-LABAs'. It has recently gained approval in Europe, and is pending regulatory review in the USA. Indacaterol produces a rapid and sustained bronchodilation that lasts for at least 24 h in patients with COPD. To date, 1-year studies with indacaterol indicate that it can be taken once daily with good overall safety and tolerability profiles. The therapeutic potential for indacaterol is supported by data on patient-reported outcomes with an improvement in symptoms such as dyspnea, exercise capacity and quality of life, and a reduction in exacerbations. It is likely that indacaterol could be used in conjunction with other agents such as inhaled corticosteroids and anticholinergics for the treatment of COPD as a single once-daily combination treatment.

• Authors: Christopher K M Hui, Kian F Chung
• Journal: Expert review of respiratory medicine (Expert Rev Respir Med) Vol. 5 Issue 1 Pg. 9-16 (Feb 2011) ISSN: 1747-6356 [Electronic] England
• PMID: 21348581 (Publication Type: Journal Article)

Chemical References

• Adrenal Cortex Hormones
• Adrenergic beta-Agonists
• Cholinergic Antagonists
• Indans
• Quinolones
• indacaterol

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Adrenergic beta-Agonists (adverse effects, pharmacokinetics, therapeutic use)
• Cholinergic Antagonists (therapeutic use)
• Drug Therapy, Combination
• Drug-Related Side Effects and Adverse Reactions
• Humans
• Indans (adverse effects, pharmacokinetics, therapeutic use)
• Pulmonary Disease, Chronic Obstructive (drug therapy, physiopathology)
• Quinolones (adverse effects, pharmacokinetics, therapeutic use)
• Treatment Outcome